About the BLOODCHIP® test
BLOODCHIP® is an integrated circuit that determines the main allelic variants of blood groups and platelet antigens by analyzing 128 genetic polymorphisms. The test is used to prevent potential transfusion reactions in those patients for whom conventional serological tests are insufficient.
The BLOODCHIP® test already holds a CE mark for marketing in Europe and has been developed by the Bloodgen Consortium, a leading European group consisting of blood banks, research institutes and Progenika Biopharma, SA., whose mission is to improve patient safety and transfusion compatibility by blood group and genotype.
Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. It focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies. In recent years Grifols has made significant investments in the area of transfusionmedicine to ensure the strategic and technological position of the company in this area.
Progenika, a Spanish company which specializes in personalized medicine., develops DNA biochips for the diagnosis, prognosis and prediction of response to treatment of complex human illnesses. Progenika offers DNA based tests in areas such as: oncology, the lipids, Nervous System diseases or the optimization of its treatments. Among its out-st
|SOURCE Grifols, Inc.|
Copyright©2010 PR Newswire.
All rights reserved